OBJECTIVE: The alpha(1A)-adrenergic receptor is highly expressed in human vasculature including resistance arteries and veins, and its stimulation is primarily responsible for adrenergically mediated smooth muscle contraction. Variability in sensitivity to phenylephrine, an alpha(1A) adrenergic agonist, has a large genetic component. We examined the hypothesis that a common polymorphism of alpha(1A)-adrenergic receptor (Arg347Cys) affects in vivo response. METHODS: We measured vascular sensitivity to phenylephrine using the dorsal hand vein linear variable differential transformer technique and determined alpha(1A)-adrenergic receptor genotype in 74 healthy, nonsmoking adults (28 Arg/Arg, 30 Arg/Cys, and 16 Cys/Cys). RESULTS: Sensitivity to phenylephrine, expressed as the dose of phenylephrine resulting in 50% venoconstriction (Phe(50)), was not significantly different in subjects with the 3 alpha(1A) adrenergic receptor genotypes: Phe(50) geometric mean (95% confidence interval) was 513 ng/min (287-918 ng/min) for Arg/Arg, 431 ng/min (274-680 ng/min) for Arg/Cys, and 471 ng/min (197-1124 ng/min) for Cys/Cys (P =.90). CONCLUSION: We conclude that the Arg347Cys receptor polymorphism does not alter agonist-mediated venoconstriction in vivo.
OBJECTIVE: The alpha(1A)-adrenergic receptor is highly expressed in human vasculature including resistance arteries and veins, and its stimulation is primarily responsible for adrenergically mediated smooth muscle contraction. Variability in sensitivity to phenylephrine, an alpha(1A) adrenergic agonist, has a large genetic component. We examined the hypothesis that a common polymorphism of alpha(1A)-adrenergic receptor (Arg347Cys) affects in vivo response. METHODS: We measured vascular sensitivity to phenylephrine using the dorsal hand vein linear variable differential transformer technique and determined alpha(1A)-adrenergic receptor genotype in 74 healthy, nonsmoking adults (28 Arg/Arg, 30 Arg/Cys, and 16 Cys/Cys). RESULTS: Sensitivity to phenylephrine, expressed as the dose of phenylephrine resulting in 50% venoconstriction (Phe(50)), was not significantly different in subjects with the 3 alpha(1A) adrenergic receptor genotypes: Phe(50) geometric mean (95% confidence interval) was 513 ng/min (287-918 ng/min) for Arg/Arg, 431 ng/min (274-680 ng/min) for Arg/Cys, and 471 ng/min (197-1124 ng/min) for Cys/Cys (P =.90). CONCLUSION: We conclude that the Arg347Cys receptor polymorphism does not alter agonist-mediated venoconstriction in vivo.
Authors: Beilei Lei; Daniel P Morris; Michael P Smith; Laura P Svetkey; Mark F Newman; Jerome I Rotter; Thomas A Buchanan; Stephen M Beckstrom-Sternberg; Eric D Green; Debra A Schwinn Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2005-03-10 Impact factor: 3.000
Authors: Jussi P Posti; Perttu Salo; Saku Ruohonen; Laura Valve; Mordechai Muszkat; Gbenga G Sofowora; Daniel Kurnik; C Michael Stein; Markus Perola; Mika Scheinin; Amir Snapir Journal: Pharmacogenet Genomics Date: 2013-03 Impact factor: 2.089
Authors: Abiodun Adefurin; Laxmi V Ghimire; Utkarsh Kohli; Mordechai Muszkat; Gbenga G Sofowora; Sachin Y Paranjape; C Michael Stein; Daniel Kurnik Journal: Hypertension Date: 2013-02-11 Impact factor: 10.190
Authors: Zhila Taherzadeh; Lizzy M Brewster; Gert A van Montfrans; Ed VanBavel Journal: J Clin Hypertens (Greenwich) Date: 2010-06 Impact factor: 3.738
Authors: A Adefurin; L V Ghimire; U Kohli; M Muszkat; G G Sofowora; C Li; S Y Paranjape; C M Stein; D Kurnik Journal: Pharmacogenomics J Date: 2014-11-25 Impact factor: 3.550
Authors: A Adefurin; L V Ghimire; U Kohli; M Muszkat; G G Sofowora; C Li; R T Levinson; S Y Paranjape; C M Stein; D Kurnik Journal: Pharmacogenomics J Date: 2016-04-19 Impact factor: 3.550